Saltar al contenido principal
xMedica

NCT07830719ClinicalTrials.gov

Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP

A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Study of YMI024 to Assess Efficacy in Reducing Inflammatory Markers, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP

En reclutamientoAdmite participantes ahora, según el registro.
Contactar con este estudio

En resumen

The purpose of this Phase 2b study is to investigate the efficacy in reducing systemic inflammation, safety, tolerability, and dose response of five doses of YMI024, as compared to placebo in adult participants with stable coronary artery disease (CAD) and…

Fase 2180 participantes buscados23 centros5 países

Categorías

Registrado en 1 registro

Un mismo estudio puede estar registrado en varios registros. Lo mostramos una sola vez y enlazamos con todos los registros que tenemos.

La información del ensayo se muestra tal como la publicó el registro, en su idioma original.

¿Le interesa este estudio?

Iniciar sesión o cree una cuenta para registrar su interés y seguir este estudio.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Not stated: Registered after enrolment began (about 3 days after the recorded start)First posted 2026-09-21; recorded start 2026-09-18
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 1147 other studies in this databaseCounted from the lead sponsor named in the record (Novartis Pharmaceuticals)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a phase 2 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm13/15

    Placebo / sham control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre0/8

    Single site, or site count not stated

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleSMALL

A small study, international in scope: 180 participants (target), run at 23 sites, across 5 countries.

How this score is built
  • Enrolment21/40

    180 participants (target)

  • Site count0/25

    1 sites

  • Country count0/15

    Single country

  • Planned duration5/10

    Planned over about 13 months

  • Sponsor scale10/10

    Novartis Pharmaceuticals has led 1,133 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Resumen

The purpose of this Phase 2b study is to investigate the efficacy in reducing systemic inflammation, safety, tolerability, and dose response of five doses of YMI024, as compared to placebo in adult participants with stable coronary artery disease (CAD) and residual inflammatory risk defined by elevated high-sensitivity C-reactive protein (hsCRP) (≥2 mg/L)

Participants are randomized in a 1:1:1:1:1:1 ratio to one of the six arms, with stratification by comorbidity status at randomization: CAD-only, CAD+ (Heart Failure) HF, and CAD+Chronic Kidney Disease (CKD), and receive study medication on top of stable standard-of-care therapies. The study employs double-blinding, concealing treatment allocation from participants, Investigators, Sponsor, and study staff, with identical packaging and labelling, schedule of administration and appearance for all study drugs.

Afecciones

  • Coronary Artery Disease

Elegibilidad

Elegibilidad
SexoTodos
Edades18 Years – 80 Years
Voluntarios sanosNo

Elegibilidad tal como figura en el registro

Inclusion Criteria: 1. Signed informed consent must be obtained prior to any study specific procedures, and participant able to understand and comply with study requirements. 2. Male and female participants aged between 18-80 years (inclusive) at Screening. 3. Documented stable CAD as evidenced by presence of at least one of the following criteria: 1. Documented history of spontaneous (Type 1) myocardial infarction (MI) of presumed atherosclerotic origin that occurred at least 30 days before the start of Screening. If a Pre-screening visit is conducted, the MI must have occurred at least 30 days before that visit. Diagnosis of the qualifying MI should be based on medical records and Investigator's judgment. 2. Prior coronary revascularization (i.e. percutaneous coronary intervention (PCI) at least 30 days prior, or coronary artery bypass grafting (CABG), at least 6 months prior to Screening). * Any prior PCI must have occurred at least 30 days prior to the Screening Visit (or if conducted, prior to the Pre screening visit). * Any prior CABG must have occurred at least 6 months (i.e. 26 weeks) prior to the Screening (or if conducted, prior to the Pre-screening) Visit. 3. Angiographic or CT-imaging (e.g., Multi Detector Computed Tomography/ Computed Tomography Angiography (MDCT/CTA)) evidence of coronary atherosclerosis: ≥50% stenosis in at least one major epicardial coronary artery. 4. Coronary artery calcium (CAC) score of ≥300 AU by computed tomography. To ensure adequate representation of patients with clinically relevant comorbidities and to enable prespecified subgroup analyses, the trial will include participants with key comorbidities as follows: i. Moderate CKD Participants with moderate (Stage 3a/3b) kidney disease (CKD) defined as: Estimated Glomerular Filtration Rate (eGFR) ≥30 and ≤60 mL/min/1.73 m² (CKD EPI formula) at Screening. ii. Chronic HF Participants with a history of chronic heart failure (HF) defined as: * NYHA Class II-III symptoms of HF requiring ongoing treatment with diuretics (loop diuretics, thiazide diuretics, and/or mineralocorticoid receptor antagonists) for ≥30 days prior to Screening, AND * LVEF ≤40%, assessed by any standard modality (e.g., echocardiography, cardiac Magnetic Resonance Imaging (MRI), CT, MUGA, or ventricular angiography) on the most recent assessment within 12 months prior to Screening. 4. Participants must have hsCRP levels ≥2 mg/L at two timepoints during Screening. Screening values must be separated by a minimum of 7 days. The initial hsCRP value must be a minimum of 30 days after a qualifying MI or after any PCI performed separately from the qualifying MI, or 6 months after CABG. Note: Participants who choose to enter the optional Pre-screening period must have an hsCRP level, measured at a local laboratory, that is considered by the Investigator to be ≥2 mg/L. This Pre-screening hsCRP value (measured at the local laboratory) must be obtained at least 30 days after a qualifying MI or after any PCI performed separately from the qualifying MI, or 6 months after a CABG. Irrespective of any Pre-screening hsCRP value, all participants must have two central laboratory hsCRP levels ≥2 mg/L at the two Screening visits to be eligible for randomization into the study. Exclusion Criteria: 1. Participants with recent major cardiovascular events or procedures, including: * myocardial infarction, unstable angina, or percutaneous coronary intervention within 30 days prior to Screening (or Pre-screening, if conducted), or * coronary artery bypass grafting or other cardiac surgery within 6 months prior to Screening (or Pre-screening, if conducted). 2. Any major (cardiac or non-cardiac) surgical, interventional or endoscopic procedure (e.g: Percutaneous carotid intervention, carotid or peripheral arterial revascularization), or stroke, Transient ischemic attack (TIA), or acute limb ischemia within 12 weeks prior to Screening or Pre-screening, where applicable). 3. Participants with a known systemic autoimmune or inflammatory disease (e.g., Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA)); clinically active diverticulitis or inflammatory bowel disease within 12 months prior to Screening; or a history of gastrointestinal perforation. 4. Patients with suspected or proven immunocompromised state at Screening (e.g., clinical diagnosis of Human Immunodeficiency Virus (HIV) or on antiretroviral therapy, absolute neutrophil count ≤1000/mm3) or any other medical condition in the opinion of the Investigator places the patient at unacceptable risk by receiving immunomodulatory therapy. 5. Known or suspected active infection, or chronic or recurrent infectious disease, including but not limited to: * Hepatitis B / Hepatitis C: Positive HBsAg, positive anti-HBc, positive anti-HBs, or positive anti-Hepatitis C Virus (HCV) at Screening. * Note: Participants positive for anti-HBs after HBV vaccination but negative for HBsAg and anti-HBc are eligible per local guidelines and Sponsor agreement. * Note: Participants positive for anti-HBc but negative for HBV Deoxyribonucleic Acid (DNA) receiving prophylactic HBV antiviral treatment (e.g., entecavir, lamivudine) are eligible per local guidelines and Sponsor agreement. * Note: Participants positive for anti-HCV but consistently negative for HCV RNA \>6 months after HCV antiviral treatment are eligible per local guidelines and Sponsor agreement. * Tuberculosis (TB): Active or latent TB as indicated by a positive QuantiFERON® TB Gold Plus test or T-SPOT® TB test at Screening. * Any other known active or suspected active infection, or chronic infection, or history of ongoing, chronic, or major recurrent infectious disease. 6. Participants with any of the following renal or hepatic abnormalities at Screening are excluded: 1. Renal dysfunction with Estimated Glomerular Filtration Rate (eGFR) \<30 mL/min/1.73 m² (using CKD-EPI formula; s://.kidney.org/professionals/gfr\_calculator). 2. Evidence of hepatic disease as determined by any one of the following: Aspartate Aminotransferase (AST) (Serum Glutamic Oxaloacetic Transaminase (SGOT)) or Alanine Aminotransferase (ALT) (Serum Glutamic Pyruvic Transaminase (SGPT)) \>3× ULN, or bilirubin \>1.5 mg/dL at Screening (for patients with Gilbert's syndrome, total bilirubin \<2× ULN is allowed). 7. Current or prior history of severe heart failure of New York Heart Association (NYHA) Class IV. Other protocol-defined inclusion/exclusion criteria may apply

Elegibilidad en frases sencillas

Los criterios de este registro aún no se han desglosado en frases separadas. El texto del registro anterior está completo y es la versión autorizada.

Diseño del estudio

Diseño del estudio
Tipo de estudioDe intervención
FaseFase 2
AsignaciónAleatorizado
Modelo de intervenciónPARALLEL
Propósito principalTREATMENT
EnmascaramientoQUADRUPLE (4)
Inscripción180 participantes buscados

Patrocinador y colaboradores

  • Novartis Pharmaceuticals Patrocinador

Grupos e intervenciones

  • YMI024 Dose 1EXPERIMENTAL

    Participants receive YMI024 Dose 1 in addition to standard-of-care therapies.

  • YMI024 Dose 2EXPERIMENTAL

    Participants receive YMI024 Dose 2 in addition to standard-of-care therapies.

  • YMI024 Dose 3EXPERIMENTAL

    Participants receive YMI024 Dose 3 in addition to standard-of-care therapies.

  • YMI024 Dose 4EXPERIMENTAL

    Participants receive YMI024 Dose 4 in addition to standard-of-care therapies.

  • YMI024 Dose 5EXPERIMENTAL

    Participants receive YMI024 Dose 5 in addition to standard-of-care therapies.

  • PlaceboPLACEBO_COMPARATOR

    Participants receive a matching placebo in addition to standard-of-care therapies

Intervenciones

  • Fármaco Placebo

    matching placebo

  • Fármaco YMI024

    YMI024 in different doses

Variables de resultado

  1. Variable de resultado principal

    Change from baseline in log-transformed IL-6

    Change from baseline in log-transformed Interleukin-6 (IL-6) to evaluate the dose-response relationship using the Multiple Comparison Procedures (MCP) component of the Multiple Comparison Procedure-Modelling (MCP-Mod) methodology

    Plazo Baseline and approximately 3 months

  2. Variable de resultado secundaria

    Change from baseline in log-transformed IL-6

    Change from baseline in log-transformed IL-6 to characterize the dose-response relationship for YMI024 in IL-6 using the model-based (Mod) component of the MCP-Mod methodology

    Plazo Baseline and approximately 3 months

  3. Variable de resultado secundaria

    Change from baseline in log-transformed hsCRP

    Change from baseline in log-transformed high-sensitivity C-reactive protein (hsCRP)

    Plazo Baseline and approximately 3 months

  4. Variable de resultado secundaria

    Responder status - hsCRP <2 mg/L

    Responder status (Yes/No), defined as hsCRP \<2 mg/L

    Plazo Approximately 3 months

  5. Variable de resultado secundaria

    Responder status - hsCRP <1 mg/L

    Responder status (Yes/No), defined as hsCRP \<1 mg/L

    Plazo Approximately 3 months

  6. Variable de resultado secundaria

    Number of participants with adverse events

    Number of participants with adverse events, including abnormal vital signs, ECGs, and laboratory assessments

    Plazo Approximately 4 months

Fechas

Fechas
Fecha de inicio18 de septiembre de 2026 (real)
Finalización principal15 de agosto de 2027 (estimada)
Finalización15 de agosto de 2027 (estimada)
Primera publicación21 de septiembre de 2026 (real)
Última actualización15 de octubre de 2026
Resultados publicadosNo indicado en el registro
Estado verificado por última vezoctubre de 2026

Real significa que el evento ocurrió. Estimada significa que el patrocinador lo prevé. Ambas cosas significan algo distinto.

Ubicaciones

23 centros están en reclutamiento

Australia

Australia
CentroCiudadEstado o regiónEstado
Novartis Investigative SiteAdelaideSouth AustraliaEn reclutamiento
Novartis Investigative SiteFrankstonVictoriaEn reclutamiento
Novartis Investigative SiteMelbourneVictoriaEn reclutamiento
Novartis Investigative SiteMulgraveVictoriaEn reclutamiento

Germany

Germany
CentroCiudadEstado o regiónEstado
Novartis Investigative SiteBerlinEn reclutamiento
Novartis Investigative SiteKaiserslauternRhineland-PalatinateEn reclutamiento
Novartis Investigative SiteMannheimEn reclutamiento
Novartis Investigative SitePirnaEn reclutamiento
Novartis Investigative SiteStuttgartBaden-WurttembergEn reclutamiento

Japan

Japan
CentroCiudadEstado o regiónEstado
Novartis Investigative SiteKamakuraKanagawaEn reclutamiento
Novartis Investigative SiteKasugaiAichi-kenEn reclutamiento
Novartis Investigative SiteMatsubaraOsakaEn reclutamiento
Novartis Investigative SiteMatsudoChibaEn reclutamiento

United Kingdom

United Kingdom
CentroCiudadEstado o regiónEstado
Novartis Investigative SiteLondonEn reclutamiento

United States

United States
CentroCiudadEstado o regiónEstado
Pharma Tex ResearchAmarilloTexasEn reclutamiento
AMR MiamiCoral GablesFloridaEn reclutamiento
Eastern Shore Research InstituteFairhopeAlabamaEn reclutamiento
G and L Research LLCFoleyAlabamaEn reclutamiento
Anderson Medical ResearchFt. WashingtonMarylandEn reclutamiento
Biopharma Informatic LLCLos AngelesCaliforniaEn reclutamiento
MD Medical ResearchOxon HillMarylandEn reclutamiento
Alliance for Multispecialty ResearchWichitaKansasEn reclutamiento
Selma Medical AssociatesWinchesterVirginiaEn reclutamiento

Documentos del estudio

No hay documentos enlazados en este registro.

Cambios a lo largo del tiempo

  1. 15 de octubre de 2026

    Fecha de finalización adelantada

    Primary completion advanced 65 days

    2027-10-192027-08-15

  2. 15 de octubre de 2026

    Centro añadido

    22 sites added (23 total)

    123

  3. 24 de septiembre de 2026

    Estado modificado

    Status changed from Not yet recruiting to Recruiting

    NOT_YET_RECRUITINGRECRUITING

  4. 24 de septiembre de 2026

    Reclutamiento abierto

    Recruitment opened

    NOT_YET_RECRUITINGRECRUITING

  5. 24 de septiembre de 2026

    Fecha de finalización aplazada

    Primary completion delayed 33 days

    2027-09-162027-10-19

  6. 24 de septiembre de 2026

    Centro añadido

    1 site added (1 total)

    01